The efficient targeting of drugs to tumor cell and subsequent rapid drug release remain
primary challenges in the development of nanomedicines for cancer therapy. Here, we …

Liver cancer is one of serious diseases which threaten human life and health. Studies on the
treatment of liver cancer have attracted widespread attention. Application of nano-drug …

Cancer chemotherapy, usually as a combination of different drugs or as an adjuvant to
surgery or radiotherapy, has been successful in the treatment of some of the rarer cancers …

Since the asialoglycoprotein receptor (also known as the “Ashwell–Morell receptor” or
ASGPR) was discovered as the first cellular mammalian lectin, numerous drug delivery …

Doxorubicin-loaded PLGA nanoparticles conjugated with a new galactose-based ligand for
the specific recognition by human hepatoma cellular carcinoma cells (Hep G2) were …

The liver is an imperative organ of tremendous importance concerned with maintenance of
metabolic functions and detoxification of exogenous and endogenous challenges like …

The requirement of having multiple nanocarriers (NCs) and active agents for improved
therapy, imaging, and controlled release of medications efficiently in one platform has made …

The insult to liver by toxic materials leads to cirrhosis, hepatitis and cancer. Upon
administration, drugs accumulate in liver, which is systemically cleared by …

Ligands with the polysaccharide headgroups have been recently reported by our group to
possess enhanced interaction with asialoglycoprotein receptor (ASGPR) in silico as …

Introduction: Hepatic-targeted drug delivery systems are designed to treat diseases of the
liver. However, since there are several different types of liver diseases that are caused by …